0
Original Research: SARCOIDOSIS |

A New Tool To Assess Sarcoidosis Severity*

Yasmine S. Wasfi, MD, PhD; Cecile S. Rose, MD, MPH; James R. Murphy, PhD; Lori J. Silveira, MS; Jan C. Grutters, MD, PhD; Yoshikazu Inoue, MD, PhD; Marc A. Judson, MD, FCCP; Lisa A. Maier, MD, MSPH, FCCP
Author and Funding Information

*From the Pulmonary, Allergy and Critical Care Division (Dr. Wasfi), Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; the Division of Environmental and Occupational Health Sciences (Drs. Rose and Maier, and Ms. Silveira), Department of Medicine, and the Division of Biostatistics (Dr. Murphy), National Jewish Medical and Research Center, Denver, CO; Heart Lung Center Utrecht (Dr. Grutters), Department of Pulmonology, St. Antonius Hospital, Utrecht, the Netherlands; the Department of Diffuse Lung Diseases and Respiratory Failure (Dr. Inoue), Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan; and the Division of Pulmonary and Critical Care Medicine (Dr. Judson), Department of Medicine, Medical University of South Carolina, Charleston, SC.

Correspondence to: Lisa A. Maier, MD, MSPH, FCCP, National Jewish Medical and Research Center, 1400 Jackson St, Room G-216, Denver, CO 80206; e-mail: maierl@njc.org



Chest. 2006;129(5):1234-1245. doi:10.1378/chest.129.5.1234
Text Size: A A A
Published online

Study objectives: Sarcoidosis is a granulomatous disorder primarily affecting the lung, but with frequent extrapulmonary organ involvement. There are no comprehensive scoring systems for sarcoidosis disease severity. Our goal was to develop and validate an objective and comprehensive sarcoidosis disease severity scoring system.

Design: Three sarcoidosis experts reviewed clinical data on 104 patients with biopsy-confirmed sarcoidosis. Each expert independently scored disease severity using a visual analog scale. Interrater agreement was assessed. Univariate analysis was performed, and those variables with p values ≤ 0.25 were used in backward regression multivariable analysis. A model was obtained including variables with a p value of ≤ 0.15 to predict severity scores. This model was subsequently validated using an independent panel of three additional international experts.

Setting: Granuloma clinic at National Jewish Medical and Research Center.

Patients: A total of 104 patients with biopsy-confirmed sarcoidosis.

Interventions: None.

Measurements and results: Pairwise assessment of interrater agreement yielded high degrees of correlation with Spearman correlation coefficients of 0.86 to 0.89 and an intraclass correlation coefficient of 0.87. Univariate analysis showed that smoking status, immunosuppressive therapy, percent predicted for diffusing capacity of the lung for carbon monoxide (Dlco), FEV1, FVC, and total lung capacity, FEV1/FVC ratio, disease duration, sites of organ involvement, and African-American race were associated with mean severity score. The multivariable model included cardiac and neurologic involvement, current therapy with noncorticosteroid immunosuppressive agents, Dlco percent predicted, FEV1/FVC ratio, African-American race, FVC percent predicted, and skin involvement. This model was validated using additional reviewer scores yielding Spearman correlation coefficients of 0.66 to 0.76 and an intraclass correlation coefficient of 0.74.

Conclusions: We derived an objective disease severity scoring system that incorporates data on demographics, pulmonary function, and organ involvement to produce a whole-body sarcoidosis assessment. This preliminary tool has potential applicability in the assessment of disease severity in sarcoidosis research.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Topics

sarcoidosis

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543